{"entity":{"id":"nct07025850","kind":"trial","name":"Efficacy Study of Digoxin Combined With Serplulimab and Chemotherapy in First-Line Treatment of MSS Advanced Colorectal Cancer","aka":[],"tldr":"A phase 1/2 trial of tislelizumab in colorectal cancer, run by Fudan University, not yet recruiting.","summary":"Efficacy Study of Digoxin Combined With Serplulimab and Chemotherapy in First-Line Treatment of MSS Advanced Colorectal Cancer is a phase 1/2, interventional study registered as NCT07025850 by Fudan University, with a registry enrolment figure of 20 participants, started 2025-08-01 and due to reach its primary completion in 2027-01-01. Interventions recorded: Digoxin; Fuquinitinib; Tislelizumab. Conditions listed: Colorectal Carcinoma. Primary outcome: objective response rate (ORR). Sites: China. No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07025850","url":"https://clinicaltrials.gov/study/NCT07025850"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["rectal-cancer","colon-cancer"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["tislelizumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07025850","phase":"1/2","setting":"Phase II Clinical Study of Digoxin Combined With Fruquintinib and Tislelizumab in Patients With Advanced Primary Colorectal Cancer Who Failed Standard Therapy","sponsor":"Fudan University","enrolled":20,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07025850/","neighbours":{"cancer":[{"id":"colon-cancer","kind":"cancer","name":"Colon cancer (adenocarcinoma of the colon)","route":"/cancers/colon-cancer/"},{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"tislelizumab","kind":"drug","name":"Tislelizumab","route":"/drugs/tislelizumab/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}